2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation

American Journal of Respiratory Cell and Molecular Biology

Volumn 50, Issue 4, 2014, Pages 684-689

  Griffin, Kathryn L ^a   Fischer, Bernard M ^a   Kummarapurugu, Apparao B ^a,d   Zheng, Shuo ^a,d   Kennedy, Thomas P ^b   Rao, Narayanam V ^c   Foster, W Michael ^a   Voynow, Judith A ^a,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b AUGUSTA UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Airway inflammation; Cystic fibrosis; Heparin; Neutrophil elastase

Indexed keywords

2 O,3 O DESULFATED HEPARIN; ANTIINFLAMMATORY AGENT; CHEMOATTRACTANT; HEPARIN; HIGH MOBILITY GROUP B1 PROTEIN; LEUKOCYTE ELASTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; IN VITRO STUDY; KERATINOCYTE; LUNG LAVAGE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN SECRETION; RESPIRATORY TRACT INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CHEMOTAXIS; DISEASE MODELS, ANIMAL; HEPARIN; HMGB1 PROTEIN; INTERLEUKIN-13; LEUKOCYTE ELASTASE; LUNG; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; PNEUMONIA; PROTEASE INHIBITORS;

EID: 84898716456     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0338RC     Document Type: Article

References (44)

1. Voynow JA, Scanlin TF. Cystic fibrosis. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. Fishman's pulmonary diseases and disorders, 4th ed. New York: McGraw Hill Medical; 2008. pp. 863-885.
2. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992;89:1478-1484.
3. Voynow JA, Fischer BM, Zheng S. Proteases and cystic fibrosis. Int J Biochem Cell Biol 2008;40:1238-1245.
4. Le Gars M, Descamps D, Roussel D, Saussereau E, Guillot L, Ruffin M, Tabary O, Hong SS, Boulanger P, Paulais M, et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo . Am J Respir Crit Care Med 2013;187:170-179.
5. Harris M, Firsov D, Vuagniaux G, Stutts MJ, Rossier BC. A novel neutrophil elastase inhibitor prevents elastase activation and surface cleavage of the epithelial sodium channel expressed in Xenopus laevis oocytes. J Biol Chem 2007;282:58-64. (Pubitemid 47076633)
6. Adebamiro A, Cheng Y, Rao US, Danahay H, Bridges RJ. A segment of gamma ENaC mediates elastase activation of Na+ transport. J Gen Physiol 2007;130:611-629. (Pubitemid 350179578)
7. Prulière-Escabasse V, Clerici C, Vuagniaux G, Coste A, Escudier E, Planès C. Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells. Respir Res 2010;11:141.
8. Rossier BC, Stutts MJ. Activation of the epithelial sodium channel (ENaC) by serine proteases. Annu Rev Physiol 2009;71:361-379.
9. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM; AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368:1963-1970.
10. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of in flammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012;186:857-865.
11. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006;17:189-201. (Pubitemid 43949075)
12. Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li J, Wang H, Yang H, Sharma L, Phan BD, et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med 2012;18:477-485.
13. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251. (Pubitemid 29329996)
14. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008;178:822-831.
15. Liou TG, Adler FR, Keogh RH, Li Y, Jensen JL, Walsh W, Packer K, Clark T, Carveth H, Chen J, et al. Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS ONE 2012;7:e42748.
16. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008;122:743-752.
17. Hecht I, Hershkoviz R, Shivtiel S, Lapidot T, Cohen IR, Lider O, Cahalon L. Heparin-disaccharide affects T cells: inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling. J Leukoc Biol 2004;75:1139-1146. (Pubitemid 38720658)
18. Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M, Prestwich GD, MacArthur RB, Walters BB, Hoidal JR, et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol 2010;299:C97-C110.
19. Fryer A, Huang Y-C, Rao G, Jacoby D, Mancilla E, Whorton R, Piantadosi CA, Kennedy T, Hoidal J. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 1997;282:208-219. (Pubitemid 27425543)
20. Zuhdi Alimam M, Piazza FM, Selby DM, Letwin N, Huang L, Rose MC. Muc-5/5ac mucin messenger RNA and protein expression is a marker of goblet cell metaplasia in murine airways. Am J Respir Cell Mol Biol 2000;22:253-260. (Pubitemid 30343350)
21. Voynow JA, Fischer BM, Malarkey DE, Burch LH, Wong T, Longphre M, Ho SB, Foster WM. Neutrophil elastase induces mucus cell metaplasia in mouse lung. Am J Physiol Lung Cell Mol Physiol 2004;287:L1293-L1302. (Pubitemid 39507209)
22. Meyer ML, Potts-Kant EN, Ghio AJ, Fischer BM, Foster WM, Voynow JA. NAD(P)H quinone oxidoreductase 1 regulates neutrophil elastase-induced mucous cell metaplasia. Am J Physiol Lung Cell Mol Physiol 2012;303:L181-L188.
23. Raschke WC, Baird S, Ralph P, Nakoinz I. Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 1978;15:261-267. (Pubitemid 9027529)
24. Maurya MR, Benner C, Pradervand S, Glass C, Subramaniam S. Systems biology of macrophages. Adv Exp Med Biol 2007;598:62-79.
25. Snedecor GW, Cochran WG. Statistical methods. Ames: Iowa State University Press; 1980.
26. Walsh DE, Greene CM, Carroll TP, Taggart CC, Gallagher PM, O'Neill SJ, McElvaney NG. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001;276:35494-35499.
27. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175:822-828. (Pubitemid 46631794)
28. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:917-927.
29. Naparstek E, Slavin S, Weiss L, Sidi H, Ohana M, Reich S, Vlodavsky I, Cohen IR, Naparstek Y. Low-dose heparin inhibits acute graft versus host disease in mice. Bone Marrow Transplant 1993;12:185-189. (Pubitemid 23268150)
30. Tang D, Kang R, Livesey KM, Zeh HJ III, Lotze MT. High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 2011;15:2185-2195.
31. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:995-1001. (Pubitemid 35256475)
32. Lee H, Park M, Shin N, Kim G, Kim YG, Shin J-S, Kim H. High mobility group box-1 is phosphorylated by protein kinase C zeta and secreted in colon cancer cells. Biochem Biophys Res Commun 2012;424:321-326.
33. Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, Xiao X. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 2007;81:741-747. (Pubitemid 46393551)
34. Aoshiba K, Yasuda K, Yasui S, Tamaoki J, Nagai A. Serine proteases increase oxidative stress in lung cells. Am J Physiol Lung Cell Mol Physiol 2001;281:L556-L564.
35. Fischer BM, Voynow JA. Neutrophil elastase induces MUC5AC gene expression in airway epithelium via a pathway involving reactive oxygen species. Am J Respir Cell Mol Biol 2002;26:447-452. (Pubitemid 34253929)
36. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.
37. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS; Recombinant AAT CF Study Team. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006;41:177-183. (Pubitemid 43165448)
38. Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D. Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007;29:240-250. (Pubitemid 46231900)
39. Grimbert D, Vecellio L, Delepine P, Attucci S, Boissinot E, Poncin A, Gauthier F, Valat C, Saudubray F, Antonioz P, Diot P. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med 2003;16:121-129. (Pubitemid 36702666)
40. Attucci S, Gauthier A, Korkmaz B, Delépine P, Martino MF, Saudubray F, Diot P, Gauthier F. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J Pharmacol Exp Ther 2006;318:803-809. (Pubitemid 44061254)
41. Quinn D, Weldon, S, Taggart, CC. Antiproteases as therapeutics to target inflammation in cystic fibrosis. Open Respir Med J 2010;4:20-31.
42. Diamant Z, Timmers MC, van der Veen H, Page CP, van der Meer FJ, Sterk PJ. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 1996;153:1790-1795. (Pubitemid 26187901)
43. Vectura Group plc Release: VR496 demonstrates anti-inflammatory and mucolytic activity in cystic fibrosis patients 3/25/2011 ed; 2011 [accessed 2011 Mar 25]. Available from: http://www.vectura.com/media/press-releases/2011/25- mar-2011.aspx
44. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010;14:R180.